Countering Vaccine Hesitancy: Present The Delta data!

By Author: Anukul Madaye
Total Articles: 52
Comment this article

Learn how collecting accurate data can help you with your vaccination campaigns. The latest variant of the COVID19 strain has been identified as the Delta variant and is believed to be 60% more contagious than the Alpha variant. Currently, the Delta variant is spreading faster than previous strains of the different and with more hospital admissions around the world. This response is directly related to global vaccination rates.

In the UK, data suggesting that the Delta variant with the Pfizer, BioTech and AstraZeneca, Oxford vaccines was twice as likely to be hospitalized had a positive impact on reducing these risks. However, the effectiveness of the vaccine in the year the reduction in these risks are directly related to those who are fully vaccinated or who are only receiving the first dose of the vaccine. For comparison, people who only received a dose of

Fast in the US. From January to now, preliminary data in the US suggests 99.5% of deaths are from people who have not been vaccinated. For example, Missouri has had vaccination rates of 40% and coronavirus rates have skyrocketed.

The key to all of this ...
... in presenting the data is the fact that vaccination rates are increasing slowly, but this rate is not relative to the delta spread. To combat the spread of the Delta variant, people need to get vaccinated.

All data and reports collected should show the striking effects of vaccination with Delta variants, hospital admissions, and in people who have been fully vaccinated, those who have received only one vaccination, and those who have not been vaccinated. Giving this data to people would encourage them to get vaccinated to prevent the spread and effects of new strains.

According to PHE, the UK has released a report showing that protection of the Delta variant strain for people needing hospital treatment for COVID19 is 71, ter one dose and 92, ter two doses of the OxfordAstraZeneca vaccine located. The Pfizer vaccine was 94 “effective in preventing hospitalization after the first dose and 96” after two doses.

Registering data after the COVID case makes it possible to equip vaccination campaigns with accurate and influential data that can be presented to the public. Within the public health sector, there are notification policies and procedures that routinely collect health data from individuals within a specific specialty, disease category, or in this relevant case, COVID. This is known as case monitoring, and it helps officers understand the various factors that help spread and, in some cases, contain these cases. The data from this case can help map populations based on demographics, age, immunization status, and nationality to guide immunization campaigns. This in turn supports measures to control outbreaks and prevent the spread of the disease.

Cellma allows these data fields and records to be monitored throughout the vaccination process. Which in turn can help with public health monitoring and accurate data-driven reporting. The information Cellma collects includes at least the following:

Demographic information (age, race, ethnicity, gender, etc.)

Clinical history

Epidemiological characteristics

Contact and exposure history

History of clinical disease and treatment received

For more Contact us for information on how Cellma can help you.